» Articles » PMID: 36164316

Bronchorrhea, a Rare and Debilitating Symptom of Lung Cancer: Case Report and Review of the Treatment

Overview
Date 2022 Sep 27
PMID 36164316
Authors
Affiliations
Soon will be listed here.
Abstract

Bronchorrhea, defined as production of voluminous watery sputum greater than 100 mL/d, is a debilitating symptom mostly found in end-stage lung cancer, specifically in invasive mucinous adenocarcinomas. Very rarely, it can primarily contribute to hypoxic respiratory failure and found in a critical care setting. We report a case of a 51-year-old woman diagnosed with having mucinous adenocarcinoma of the lung who presented to the intensive care unit with rapidly worsening respiratory failure and found to have massive bronchorrhea with daily sputum volume exceeding 1000 mL/d at its peak. With the limited quantity and quality of evidence available for the treatment of this condition, multiple agents were tried without considerable benefit. We discuss the pathogenesis of this condition and the different treatment options that can be used for palliation of the sputum volume.

Citing Articles

A case of invasive mucinous adenocarcinoma presenting with massive bronchorrhea.

Takata K, Kinoshita Y, Yoshimura M, Takenaka S, Utsunomiya T, Koide Y Respir Med Case Rep. 2024; 51:102082.

PMID: 39070296 PMC: 11278059. DOI: 10.1016/j.rmcr.2024.102082.


Octreotide as a novel agent for the management of bronchorrhea in mechanically ventilated patients: A case series and review of literature.

Bhandari S, Sostin O, Shah A, Chronakos J, Kahn D, Mendez J Respir Med Case Rep. 2023; 45:101891.

PMID: 37448885 PMC: 10336782. DOI: 10.1016/j.rmcr.2023.101891.

References
1.
Lembo T, Donnelly T . A case of pancreatic carcinoma causing massive bronchial fluid production and electrolyte abnormalities. Chest. 1995; 108(4):1161-3. DOI: 10.1378/chest.108.4.1161. View

2.
Remi C, Remi J, Bausewein C . Pharmacological Management of Bronchorrhea in Malignant Disease: A Systematic Literature Review. J Pain Symptom Manage. 2016; 51(5):916-25. DOI: 10.1016/j.jpainsymman.2015.12.335. View

3.
Sanz Rubiales A, de la Cruz V, Berezo J, Torres M . Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma. J Pain Symptom Manage. 2014; 47(6):e7-9. DOI: 10.1016/j.jpainsymman.2013.12.248. View

4.
Kurahara Y . Massive Bronchorrhea. Intern Med. 2021; 60(13):2155-2156. PMC: 8313929. DOI: 10.2169/internalmedicine.6602-20. View

5.
Kitazaki T, Soda H, Doi S, Nakano H, Nakamura Y, Kohno S . Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. Lung Cancer. 2005; 50(1):19-24. DOI: 10.1016/j.lungcan.2005.05.005. View